BRIEF published on 09/16/2026 at 08:05, 5 days 7 hours ago TME Pharma NV's strategy and financial commitment Biotechnology Partnerships Financial Strategy TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 5 days 7 hours ago TME PHARMA CEO MESSAGE TME Pharma CEO message emphasizes strategic approach, financial discipline, and long-term value creation for shareholders. Updates on NOX-A12, cost-reduction strategy, and future plans CEO Message Financial Discipline TME Pharma Strategic Approach NOX-A12
BRIEF published on 08/24/2026 at 08:10, 28 days 7 hours ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
PRESS RELEASE published on 08/24/2026 at 08:05, 28 days 7 hours ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
BRIEF published on 10/30/2025 at 21:05, 10 months 21 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 10 months 21 days ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 1 year ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 1 year ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
BRIEF published on 08/25/2025 at 08:05, 1 year ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
PRESS RELEASE published on 08/25/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
Published on 09/21/2026 at 14:20, 1 hour 12 minutes ago Doctor's Choice(R) Clinically-Proven Scrubs Launching on Amazon Canada
Published on 09/21/2026 at 14:05, 1 hour 27 minutes ago Winners of this Year's Semmelweis-Richter International Journalism Award Announced
Published on 09/21/2026 at 14:00, 1 hour 32 minutes ago Dateline Files Motion to Resume Operations at Colosseum
Published on 09/21/2026 at 13:45, 1 hour 47 minutes ago Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 13:30, 2 hours 2 minutes ago AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform
Published on 09/21/2026 at 15:28, 3 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 09/21/2026 at 15:05, 27 minutes ago 70mai Launches A900 Series, Led by Flagship A900 Ultra
Published on 09/21/2026 at 14:35, 57 minutes ago Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.98 Million Tokens, and Total Crypto and Total Cash Holdings of $17.1 Billion
Published on 09/21/2026 at 07:00, 8 hours 32 minutes ago Peugeot Invest takes a stake in Mérieux NutriSciences
Published on 09/18/2026 at 18:34, 2 days 20 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 3 days 21 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
